Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Morphine
Drug ID BADD_D01498
Description Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805.[A176035] It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse.[A176050] Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941.[L12114]
Indications and Usage Morphine is used for the management of chronic, moderate to severe pain.[A176050] Opiods, including morphine, are effective for the short term management of pain. Patients taking opioids long term may need to be monitored for the development of physical dependence, addiction disorder, and drug abuse.[L5728]
Marketing Status approved; investigational
ATC Code N02AA01
DrugBank ID DB00295
KEGG ID D08233
MeSH ID D009020
PubChem ID 5288826
TTD Drug ID D0WE3O
NDC Product Code 42799-217
UNII 76I7G6D29C
Synonyms Morphine | Morphia | Morphine Chloride | Chloride, Morphine | Morphine Sulfate | Sulfate, Morphine | SDZ 202-250 | SDZ 202 250 | SDZ 202250 | SDZ202-250 | SDZ202 250 | SDZ202250 | Morphine Sulfate (2:1), Pentahydrate | MS Contin | Contin, MS | Oramorph SR | Duramorph | Morphine Sulfate (2:1), Anhydrous
Chemical Information
Molecular Formula C17H19NO3
CAS Registry Number 57-27-2
SMILES CN1CCC23C4C1CC5=C2C(=C(C=C5)O)OC3C(C=C4)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Breast disorder21.05.04.004--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Gastrointestinal motility disorder07.02.03.0010.000111%Not Available
Inflammation10.02.01.089; 08.01.05.007--Not Available
Ischaemia24.04.02.0040.000111%Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.0020.002506%Not Available
Temperature regulation disorder08.05.01.004; 05.03.04.0130.000111%Not Available
Abnormal behaviour19.01.01.001--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Feeling of body temperature change08.01.09.012--Not Available
Erectile dysfunction21.03.01.007; 19.08.04.001--
Respiratory disorder neonatal18.04.09.002; 22.11.01.0020.000167%Not Available
Ill-defined disorder08.01.03.049--Not Available
Disease progression08.01.03.038--
Obstructive airways disorder22.03.01.0110.000334%Not Available
Psychotic disorder19.03.01.002--
Pulmonary function test decreased13.19.01.001--Not Available
Grimacing17.02.05.0290.000111%Not Available
Hepatobiliary disease09.01.08.003--Not Available
Renal impairment20.01.03.010--Not Available
Hyperamylasaemia14.11.01.0030.000223%Not Available
Bowel movement irregularity07.02.03.0030.000356%Not Available
Breakthrough pain16.32.03.016; 08.01.08.0260.000546%Not Available
Infusion site irritation12.07.05.011; 08.02.05.0100.000111%Not Available
Infusion site urticaria12.07.05.021; 10.01.06.010; 08.02.05.021; 23.04.02.0100.000490%Not Available
Aortic arteriosclerosis24.04.01.0040.000111%Not Available
Urethral stenosis20.07.03.003--Not Available
Cardiovascular insufficiency02.11.01.011; 24.06.03.005--Not Available
The 16th Page    First    Pre   16 17 18 19 20    Next   Last    Total 20 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene